Novo Nordisk A/S (0QIU.IL)
Makes insulin and obesity drugs for diabetes and rare blood disorders.
333.50+0.00%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+7.5%
The outlook
Novo Nordisk trades at 333.5, sitting well above both its 50- and 200-day moving averages and positioned near the upper end of its 52-week range. Analyst coverage shows a bullish lean with a score of 86/100. The stock trades at a trailing P/E of 22.4, reflecting a premium valuation in its sector.
What’s behind the score
Price trendAbove its 50- & 200-day averages
52-week range79% of the way from its 52-week low to high
Market cap
$1.40T
52-wk high
409.90
52-wk low
50.24
50-day avg
304.14
200-day avg
300.42
Trailing P/E
22.4